BioPath

Latest News
Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002Nov 19 2020
BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTSNov 13 2020
Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020Nov 6 2020
Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of CancersOct 22 2020
Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceSep 9 2020
BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTSAug 14 2020
Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid LeukemiaAug 13 2020
Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020Aug 10 2020
Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual MeetingMay 29 2020
BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTSMay 15 2020
Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual MeetingMay 13 2020
Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020May 8 2020
Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual MeetingApr 27 2020
Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual MeetingApr 13 2020
Bio-Path Holdings Appoints Ernst & Young as New AuditorMar 11 2020
BIO-PATH HOLDINGS REPORTS FULL YEAR 2019 FINANCIAL RESULTSMar 5 2020
Webcast Link to Fourth Quarter and Full Year 2019 Financial Results – Friday, March 6, 2020 at 8:30 a.m. ETFeb 28 2020
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020Feb 28 2020
Bio-Path Holdings Provides Clinical Update and 2020 Business OutlookJan 8 2020
H.C. Wainwright / BPTH: Safety Testing of Phase 2 AML Trial Completed; Financing Closed; Reiterate Buy; Adjusting PT to $25Dec 2 2019

More News

Giving Previously Untreatable Cancer Patients a Fighting Chance

We are developing targeted cancer treatments that offer effective therapy without harsh side effects so that even the most fragile patients can have tolerable treatment options.

About Us

DNAbilize^®

The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy.

Learn More

Our Patients

Prognosis for these older cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for older, fragile cancer patients who are unfit or ineligible for high-dose chemotherapy.

A new path in DNA-powered medicine.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize^®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

Latest News

Giving Previously Untreatable Cancer Patients a Fighting Chance

DNAbilize®

Our Patients

Our Products

Delivering a Better Path for Cancer Patients.

DNAbilize^®